Published in Vaccine Weekly, July 7th, 1997
TBC-3B is a recombinant vaccine for the prevention of AIDS. The trial is the first study to evaluate TBC-3B in vaccinia-naive individuals, the potential target population, and to combine the vaccine with boosts of gp120, an HIV specific envelope glycoprotein developed by VaxGen, Inc., formerly part of Genentech, Inc. The clinical trial is being conducted at NIAID's six AIDS Vaccine Evaluation Units across the country.
"Therion's TBC-3B represents a unique...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly